Your browser doesn't support javascript.
loading
Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
Tanzawa, Shigeru; Ishihara, Masashi; Haruyama, Terunobu; Ochiai, Ryosuke; Sakamoto, Takahiko; Honda, Takeshi; Ota, Shuji; Ichikawa, Yasuko; Watanabe, Kiyotaka; Seki, Nobuhiko.
Afiliação
  • Tanzawa S; Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
  • Ishihara M; Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
  • Haruyama T; Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
  • Ochiai R; Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
  • Sakamoto T; Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
  • Honda T; Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
  • Ota S; Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
  • Ichikawa Y; Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
  • Watanabe K; Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
  • Seki N; Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Transl Cancer Res ; 8(6): 2223-2229, 2019 Oct.
Article em En | MEDLINE | ID: mdl-35116975
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article